3rd Annual Innate Killer Summit

Date: 27-Mar-18 to 29-Mar-18
Location: The DoubleTree by Hilton Hotel San Diego – Mission Valley / United States
Category: Healthcare & Pharmaceuticals Conferences & Trade Fairs

As the cell immunotherapy field continues to explode beyond the well-hyped CAR-Ts, the Innate Killer Summit 2018 gathers the leading scientific and business experts from all the key stakeholders to identify future approaches to deliver commercially viable off-the-shelf therapies.

By harnessing the unique power of the innate immune system, seize the enhanced drug development opportunity of NK cell immunotherapies. Capitalize on a more robust allogeneic development approach that overcomes common safety concerns experienced by other cell therapies.

The 3rd Innate Killer Summit offers the platform for experts and leaders in the Innate Killer Community to come together, network and create collaborative partnerships.

Learn from case studies on:

- Increasing Persistency and Specificity with CAR-NK – novel clinical data outlining methods to redirect NK
cell specificity and in vivo persistence

- Combination Therapies to Support and Enhance Immunotherapeutic Response – explore the use of targeted antibodies and cytokines to work alongside NK cells to improve their role in persistence and anti-tumor effects

- Off-the-Shelf Allogeneic Therapies to Improve Accessibility of Treatment – utilize the capability of administering NK therapies as an “Off-the-Shelf” living drug

- Manufacturing Considerations to Improve Proliferation in NK Clinical Trials – create solutions to manufacturing hurdles specifically in regards to scaling up, expansion and increasing NK proliferative capabilities

- Regulatory Outline to Ensure Safety and Efficacy in NK Clinical Trials – identify the regulatory framework and procedures that surround NK research area

Exhibitors

Jeffrey Miller, Professor of Medicine, University of Minnesota, Wilfred Germeraad, Chief Scientific Officer, Chief Operating Officer & Co-Founder, Cimaas, Katy Rezvani, Chief, Section of Cellular Therapy at Department of Stem Cell Transplantation and Cellular Therapy MD Anderson, Cancer Center, Michael Caligiuri, Director of the Comprehensive Cancer Center CEO, James Cancer Hospital and Solove Research Institute, Ohio State University, Bob Valamehr, Vice President, Cancer Immunotherapy and Reprogramming Biology, Fate Therapeutics, Karl-Johan Malmberg, Professor of Immunology, University of Oslo, Joachim Koch Professor of Biochemistry, Goethe-University Frankfurt and Research Program Head Affimed, Mark Lowdell, Professor, Cell and Tissue Therapy, University College London, Sang Hoon Paik, General Manager / Head of Process Unit, Greencross, Nicholas Huntington, Molecular Immunology Laboratory Head, Walter and Eliza Hall Institute of Medical Research, Jan Spanholtz, Chief Scientific Officer and Research and Development Manager, Glycostem Therapeutics, Dan Kaufman, Professor of Medicine & Director of Cell Therapy, University of California, Sandip Patel, Assistant Professor, Medical Oncology/Hematology, UC San Diego Moores Cancer Center, Robin Pariha, r Assistant Professor, Center for Cell and Gene Therapy, Baylor College of Medicine, Eugene Zhukovsky, Chief Scientific Officer, Biomunex Pharmaceuticals, Katharine Hsu, Attending Physician and Member, Bone Marrow Transplantation, Memorial Sloan Kettering Cancer Center, Raymond Urbanski, Chief Medical Officer, GT Biopharma, Steve Doberstein, Chief Scientific Office and Senior Vice President of Research, Nektar Therapeutics

Go to event website